Get the Stockscreener App
0.9934
5.39%
-0.0566
Annovis Bio Inc stock is traded at $0.9934, with a volume of 641.42K.
It is down -5.39% in the last 24 hours and down -4.48% over the past month.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
See More
Previous Close:
$1.05
Open:
$1.06
24h Volume:
641.42K
Relative Volume:
1.01
Market Cap:
$42.40M
Revenue:
Net Income/Loss:
$-40.92M
P/E Ratio:
-0.5787
EPS:
-1.7167
Net Cash Flow:
$-26.53M
1W Performance:
-17.90%
1M Performance:
-4.48%
6M Performance:
-44.19%
1Y Performance:
-51.06%
1-Day Range:
$0.987
$1.08
1-Week Range:
$0.987
$1.21
52-Week Range:
$0.987
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
0.9934 | 42.40M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-26 | Initiated | Roth Capital | Buy |
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Uses AI Platform to Accelerate Buntanetap FDA Filing - MyChesCo
Annovis Bio stock reports 862 Phase 3 enrollments - ad-hoc-news.de
Annovis Bio, Inc. Announces Partnership With Weave Bio In Preparation Of NDA For Buntanetap In Alzheimer?s Disease - marketscreener.com
Annovis Bio partners with Weave Bio for NDA preparation By Investing.com - Investing.com Australia
Annovis Bio partners with Weave Bio for NDA preparation By Investing.com - Investing.com Canada
Annovis Bio partners with Weave Bio for NDA preparation - Investing.com
Annovis Announces Partnership with Weave Bio, AI Regulatory - GlobeNewswire
Annovis Bio announces special shareholder meeting - Bitget
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Annovis Bio stock reacts to webinar plan and steep discount to analyst targets - ad-hoc-news.de
Annovis Bio Stock Price Forecast. Should You Buy ANVS? - StockInvest.us
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA - TradingView
ANVS: Top-line phase III Alzheimer's data expected in March, with NDA filing and funding plans in place - TradingView
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Momentum Breakout Ideas - vinanet.vn
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Andrews Pitchfork - dars.gov.et
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesBearish Pattern Stocks - vinanet.vn
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesMFI Divergence - dars.gov.et
ANVS Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineProfit Announcement - vinanet.vn
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Annovis to Host Corporate Update Webinar on September 2, 2026 - Yahoo Finance
Annovis says Alzheimer’s trial is fully enrolled, with data expected in 2027 - Stock Titan
Annovis (ANVS) Results Breakdown: Profit Per Share Falls Below Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - theglobeandmail.com
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Trend Continuation Trade - dars.gov.et
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Caledonian Record
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - GlobeNewswire
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annovis Bio Inc Stock (ANVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoffman Michael B | Director |
Apr 02 '26 |
Buy |
2.10 |
713,800 |
1,498,980 |
3,288,539 |
| White Mark K. | Director |
Apr 02 '26 |
Proposed Sale |
2.08 |
7,142 |
14,848 |
0 |
| Hoffman Michael B | Director |
Dec 08 '25 |
Buy |
4.31 |
45,000 |
193,794 |
2,574,739 |
| Hoffman Michael B | Director |
Nov 24 '25 |
Buy |
4.08 |
39,200 |
159,886 |
2,519,739 |
| Hoffman Michael B | Director |
Nov 21 '25 |
Buy |
3.50 |
20,000 |
69,900 |
2,490,539 |
| Hoffman Michael B | Director |
Nov 14 '25 |
Buy |
2.11 |
15,000 |
31,650 |
2,470,539 |
| Maccecchini Maria-Luisa | President & CEO |
Oct 28 '25 |
Buy |
2.05 |
97,561 |
200,000 |
1,212,020 |
| Hoffman Michael B | Director |
Oct 28 '25 |
Buy |
2.05 |
975,610 |
2,000,000 |
2,455,539 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):